以色列国家HPV免疫规划实施后生殖器疣发病率显著下降
该回顾性研究利用Maccabi Healthcare Services去标识化数据,分析2006至2022年10-65岁人群生殖器疣(AGW)发病率。结果显示,自国家免疫规划(NIP)实施前至性别中立疫苗接种期后,10-14岁、15-17岁和18-21岁女性AGW发病率分别下降64%、65%和37%,10-14岁和15-17岁男性分别下降60%和45%;但NIP未覆盖的21岁以上男性AGW发病率上升,与衣原体和淋病发病率上升一致。
要点
- HPV免疫规划实施后,疫苗覆盖年龄组生殖器疣发病率显著下降。
- 10-14岁女性AGW发病率降幅最大(64%),男性同龄组降60%。
- NIP未覆盖的21岁以上男性AGW发病率上升,需扩大疫苗可及性。
核心结论
- 以色列实施HPV国家免疫规划后,生殖器疣发病率显著下降。
- NIP未覆盖的成年男性AGW发病率上升,提示需改善青少年NIP之外的疫苗接种可及性。
研究设计与样本
- 回顾性研究,使用Maccabi Healthcare Services去标识化数据,纳入2006至2022年10-65岁个体,按性别、年龄组和出生队列分层。
- 采用泊松回归比较NIP前(2006-2008)、性别中立疫苗围期(2014-2016)和性别中立疫苗后期(2016-2022)的发病率。
- 以衣原体和淋病发病率作为负对照结局,评估性行为变化的可能影响。
主要发现
- 女性10-14岁、15-17岁和18-21岁AGW发病率从NIP前至性别中立疫苗后期分别下降64%、65%和37%,45-65岁女性略升。
- 男性10-14岁和15-17岁AGW发病率分别下降60%和45%,18-21岁下降延迟,随接种队列年龄增长而显现。
- NIP未覆盖的21岁以上男性AGW发病率上升,与衣原体和淋病发病率上升一致。
- NIP实施后,符合NIP年龄条件的各单岁年龄组AGW发病率呈逐渐下降趋势。
- 所有出生队列中AGW发病率随年龄增长而增加,但疫苗可及队列的增加幅度较小。
临床怎么用
- HPV免疫规划对青少年生殖器疣防控效果显著,应维持高接种覆盖率。
- 关注NIP未覆盖成年男性的生殖器疣上升趋势,评估扩展疫苗接种年龄的可行性。
局限性
- 原文未报告研究局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Israel's National Immunization Program (NIP) for human papillomavirus (HPV) began in 2013 for 13-year-old girls with the 2-valent vaccine (2vHPV), switched to the 4-valent vaccine (4vHPV) in 2014, expanded to a gender-neutral (GNV) program in 2015, and adopted the 9-valent vaccine (9vHPV) in 2019. Both 4v- and 9vHPV vaccines protect against HPV types 6 and 11, which cause over 95% of anogenital warts (AGW). This study examined the incidence of AGW following Israel's HPV-NIP. METHODS: This retrospective study used de-identified data from Maccabi Healthcare Services (MHS) to examine AGW incidence among individuals aged 10-65 years from 2006 to 2022, stratified by sex, age group, and birth cohort. Poisson regression was employed to compare incidence across pre-NIP (2006-2008), peri-GNV (2014-2016), and post-GNV (2016-2022) periods. Chlamydia and gonorrhea incidence rates served as negative control outcomes for possible changes in sexual behavior. RESULTS: AGW incidence declined by 64%, 65%, and 37% from pre-NIP to post-GNV period among females aged 10-14,15-17, and 18-21, respectively, while slightly increasing among women aged 45-65. Among males, incidence decreased by 60% and 45% in the 10-14 and 15-17 age groups, respectively, with a delayed decline among 18-21-year-olds as vaccinated cohorts aged in. However, among men aged >21, ineligible for the NIP, AGW incidence increased, mirroring a rise in chlamydia and gonorrhea incidence. Moreover, a gradual post-NIP decline in AGW incidence was observed across NIP-eligible one-year age groups. While AGW incidence increased with age across all cohorts, the increase was less pronounced among vaccine-eligible cohorts. CONCLUSION: AGW incidence significantly declined following NIP implementation. However, the increase in AGW incidence among NIP-ineligible adults emphasizes the need to improve vaccination access beyond adolescent NIP.
引用
- Shapiro I, Tadese BK, Hoshen M, et al. A significant decrease in anogenital warts incidence following the implementation of a national human papillomavirus immunization program in Israel. Vaccine. 2026. PMID: 41895155. doi:10.1016/j.vaccine.2026.128516
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。